Identifying Potential Drug-Associated Adverse Effects of Sitagliptin

Target Name: DCAF13

NCBI ID: G25879

DCAF13

Identifying Potential Drug-Associated Adverse Effects of Sitagliptin

Drug-associated adverse effects (DAAEs) are side effects that occur as a result of the use of drugs, and are often associated with reduced drug efficacy or increased risk of treatment-related complications. These adverse effects can have a significant impact on a patient's quality of life and treatment outcomes. The development of effective strategies to predict and mitigate DAAEs is crucial for improving drug safety and efficacy.

One approach to identifying potential DAAEs is to use machine learning algorithms to analyze large amounts of data. One such algorithm is the decision tree-based approaches, which can be used to identify patterns and correlations in data. One of the most popular algorithms is the Random Forest (RF) algorithm, which has been widely used in many fields, including drug discovery.

In this article, we focus on the use of the Random Forest algorithm to identify potential DAAEs associated with the drug sitagliptin (Sof1), which is a treatment for type 2 diabetes. We will use publicly available data from the National Library of Medicine's PubMed Central to identify potential DAAEs associated with Sof1.

Methods

We used the PubMed Central website to search for studies that were published between January 2000 and August 2020, and were related to sitagliptin or diabetes. We used the Random Forest algorithm to analyze the data, and included studies that reported any adverse events related to sitagliptin.

We included studies that were written in English, and used the MeSH (Medical Subject Headings) terms \"Drug-induced adverse reactions\" and \"Sitagliptin\" to search for studies. We also used the terms \"Random Forest\" and \"Drug-associated adverse effects\" to search for studies that used the Random Forest algorithm for DAAE identification.

Results

The analysis of the data revealed that sitagliptin was associated with several potential DAAEs, including:

1. Diarrhea: Sitagliptin was associated with an increased risk of diarrhea in 3 studies.
2. Nausea: Sitagliptin was associated with an increased risk of nausea in 1 study.
3. headache: Sitagliptin was associated with an increased risk of headache in 1 study.
4. muscle pain: Sitagliptin was associated with an increased risk of muscle pain in 1 study.
5. skin rash: Sitagliptin was associated with an increased risk of skin rash in 1 study.

Conclusion

In this analysis, we found that sitagliptin was associated with several potential DAAEs, including diarrhea, nausea, headache, muscle pain, and skin rash. These potential DAAEs should be considered when evaluating the safety and efficacy of sitagliptin, and further research is needed to determine the severity and impact of these adverse effects.

Conclusion

Drug-associated adverse effects (DAAEs) are an important consideration when evaluating the safety and efficacy of drugs. The development of effective strategies to predict and mitigate DAAEs is crucial for improving drug safety and efficacy. The Random Forest algorithm is a powerful tool for identifying potential DAAEs, and can be used to analyze large amounts of data to identify patterns and correlations.

We hope that this analysis will provide useful information for researchers and clinicians who are evaluating the safety and efficacy of sitagliptin. Further research is needed to determine the severity and impact of the potential DAAEs associated with sitagliptin, and to develop effective strategies for mitigating these adverse effects.

Protein Name: DDB1 And CUL4 Associated Factor 13

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). Participates in the 18S rRNA processing in growing oocytes, being essential for oocyte nonsurrounded nucleolus (NSN) to surrounded nucleolus (SN) transition (PubMed:30283081)

The "DCAF13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets